secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038570
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026
--------------------------------------------------------------------------------

- Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.
- Cash and short-term investments $113.3M as of June 30, 2025; expected to fund operations into 2028.
- Phase 2 LOTUS trial (AVTX-009 in hidradenitis suppurativa) enrollment >75% complete; topline data expected mid-2026.
- R&D expenses increased to $14.1M from $4.6M, largely due to the Phase 2 LOTUS trial.
- Rita Jain, M.D. appointed to Board of Directors; brings clinical development and regulatory experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/0001628280-25-038570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/avtx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer